Roche plots new course for tiragolumab as execs navigate biosimilar challenges and declining Covid-19 sales

Nicole DeFeudis

Editor

Roche’s tiragolumab flop earlier this quarter set the program back at least a year, Severin Schwan revealed on the company’s Q2 call — but the outgoing …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

TRENDING NOW

Roche plots new course for tiragolumab as execs navigate biosimilar challenges and declining Covid-19 sales

Nicole DeFeudis

Editor

Sign up to read this article for free.

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

In blow to compounders, FDA reaffirms tirzepatide shortage is over

Updated: Vertex’s non-opioid pill disappoints in mid-stage chronic pain study

Regeneron forges ahead in factor XI despite field’s mixed results

FDA rejects Zealand Pharma's short bowel syndrome drug

Bristol Myers pays $100M upfront to collaborate with Leqembi originator in Alzheimer's

Roche plots new course for tiragolum­ab as ex­ecs nav­i­gate biosim­i­lar chal­lenges and de­clin­ing Covid-19 sales

Nicole DeFeudis

Editor

Sign up to read this article for free.

more like this

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

In blow to com­pounders, FDA reaf­firms tirzepatide short­age is over

Up­dat­ed: Ver­tex’s non-opi­oid pill dis­ap­points in mid-stage chron­ic pain study

Re­gen­eron forges ahead in fac­tor XI de­spite field’s mixed re­sults

FDA re­jects Zealand Phar­ma's short bow­el syn­drome drug

Bris­tol My­ers pays $100M up­front to col­lab­o­rate with Leqem­bi orig­i­na­tor in Alzheimer's

Roche plots new course for tiragolumab as execs navigate biosimilar challenges and declining Covid-19 sales

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

In blow to compounders, FDA reaffirms tirzepatide shortage is over

Updated: Vertex’s non-opioid pill disappoints in mid-stage chronic pain study

Regeneron forges ahead in factor XI despite field’s mixed results

FDA rejects Zealand Pharma's short bowel syndrome drug

Bristol Myers pays $100M upfront to collaborate with Leqembi originator in Alzheimer's